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Summary The search for an ‘ideal’ agent for pleurodesis continues. Iodopovidone
is a topical antiseptic and has been shown to be safe and effective in many studies.
The aim of this study was to evaluate the efficacy and safety of iodopovidone as an
agent for chemical pleurodesis. We performed a systematic review of all the
observational trials which have used iodopovidone for chemical pleurodesis. Six
studies including 265 patients who had undergone chemical pleurodesis with
iodopovidone were included for this analysis. Iodopovidone was used for variety of
indications, which included pleural effusion (157 patients), and pneumothorax (108
patients). Pleurodesis was performed through tube thoracostomy in 144 patients and
through thoracoscopy in 121 patients. The success rate of pleurodesis varied from
64.2% to 100%, and summary success rate of all the studies was 90.6% (95%
confidence intervals [CI], 86.4–93.8). The success rate was independent for the
procedure (tube thoracostomy [126/144; 87.5%, 95% CI 80.9–92.4] or thoracoscopy
[114/121; 94.2%, 95% CI 88.4–97.6]) used for performing pleurodesis or for the
indication (pleural effusion [139/157; 88.5%, 95% CI 82.5–93.1] or pneumothorax
[101/108; 93.5%, 95% CI 87.1–97.4]). The only significant complication reported was
chest pain of varying degree. Systemic hypotension was reported in three patients in
only one study. There were no deaths related to chemical pleurodesis with
iodopovidone. Overall, this review supports the safety and efficacy of iodopovidone
as an agent for chemical pleurodesis in cases of recurrent pleural effusions and
pneumothoraces regardless of their etiology.
& 2006 Elsevier Ltd. All rights reserved.
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Introduction
Pleurodesis is a method to achieve a symphysis
between two layers of the pleura in order to
prevent accumulation of either air or fluid in the
pleural space. The methods of pleurodesis include
surgical abrasion with a dry gauze sponge through
thoracotomy or video-assisted thoracoscopic sur-
gery (VATS), or intrapleural instillation of a scleros-
ing agent through tube thoracostomy or through
VATS. A plethora of chemical agents have been used
for pleurodesis in the literature,1 and include talc,2
tetracyclines,3 quinacrine,4 antineoplastic drugs
(bleomycin, mitomycin, nitrogen mustard),5 immu-
nomodulating agents (interferon [IFN]-alpha and
IFN-gamma),6,7 silver nitrate,8 biological agents
(suspension of killed Corynebacterium parvum or
Streptococcus pyogenes [OK 432]),9–11 and finally
iodopovidone.12 An ideal sclerosing agent should
have a high molecular weight and chemical polarity,
low regional clearance, rapid systemic clearance, a
steep dose-response curve, and should be well
tolerated with minimal or no side effects.13 Such
an ‘ideal’ agent remains undiscovered and the
choice of a particular agent depends on the local
availability and experience. The recently published
International Survey of Pleurodesis Practice sur-
veyed pulmonologists in five different English-speak-
ing countries (USA, Canada, UK, Australia, and New
Zealand) on their management of malignant pleural
effusions, and found that talc was the agent of
choice in 68% of the 859 respondents surveyed,
followed by tetracycline derivatives and bleomycin
(26% and 6%, respectively).14 Talc is cheap and
readily available at many centers but serious
concerns have been raised about the safety of talc.
There are reports of acute respiratory distress
syndrome following the administration of talc with
many patients succumbing to the complication.15,16
We have recently analyzed our experience of
chemical pleurodesis with iodopovidone in patients
with both pleural effusion and pneumothorax, and
found its efficacy rate of 89.1%.12 Although the first
report of chemical pleurodesis with iodopovidone was
published in 1991,17 it is only recently that interest
has been rekindled in this agent because of its safety
and easy availability. In view of the low cost and wide
availability of this commonly used drug, it is important
to analyze its efficacy and safety in large number of
patients for recommending its widespread use. This
systematic review is an attempt in this direction.
Material and methods
To identify the studies for inclusion in this review, all
the authors independently searched the National
Library of Medicine’s MEDLINE database for relevant
studies published from 1966 till current date using
free text terms : chemical pleurodesis, pleurodesis
and/or iodopovidone, pleurodesis and/or betadine.
Bibliographies of all selected articles and review
articles that included information on iodopovidone
pleurodesis were reviewed for other relevant arti-
cles. In addition, we reviewed our personal files.
All the studies irrespective of language was identi-
fied. The abstracts of the studies were indepen-
dently reviewed by two authors (RA and ANA),
without blinding to study the details. Any disagree-
ment was resolved by discussion between the
authors. Data was recorded on a standard data
extraction form.
The following items were extracted:
 Publication details (title; author(s); other cita-
tion details)
 Patient details
 Outcome measures (success rate of iodopovi-
done pleurodesis—defined as the absence of
pleural fluid during follow-up)
 Complications related to the procedure
Statistical analysis
To calculate the efficacy of iodopovidone pleurod-
esis, we used binomial proportions in which the
numerator was the success rate and denominator
the total study population. The expected propor-
tion was the success rate of each study included.
We then calculated the 95% confidence intervals
(CI) for the expected proportion using the New-
combe-Wilson method.18,19 The data from indivi-
dual studies was then pooled, and a summary
success rate with 95% CI was calculated. The
difference between two proportions was assessed
by the Chi-square test and the iterative method of
Miettinen and Nurminen was used to construct the
confidence interval for the difference between the
proportions.18 Heterogeneity could be assessed
only qualitatively by visual inspection of the Forest
plot because of the study design of abstract patient
data and inclusion of observational studies.20 The
statistical package StatsDirect version 2.4.5 was
used to perform the statistical analysis.
The institutional review board clearance was not
required for this manuscript as this was a meta-
analysis of observational studies.
Results
Our initial data search yielded a total of 1195
citations of studies that have used chemical
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pleurodesis. We excluded 1185 articles by review-
ing titles and abstracts as they did not involve
pleurodesis with iodopovidone. We selected ten
articles for our analysis. The inclusion criteria
included the use of iodopovidone as an agent for
pleurodesis, reporting the technique used for
pleurodesis, the side-effects and the outcome of
the pleurodesis. We also excluded case-reports. Of
these ten articles, six met the inclusion criteria and
were included in the analysis.12,17,21–24 Four studies
were excluded as three of them were case reports
and one was a letter to the editor. All the six
studies were of observational nature. The char-
acteristics of the patients and the methods used for
pleurodesis are summarized in Table 1. Qualitative
assessment of heterogeneity based on the amount
of disparity among the individual point estimates
and the degree of overlap among the confidence
intervals was negligible (Fig. 1).
The total number of patients in all the studies
included 265 patients. Iodopovidone was used for
variety of indications, which included pleural
effusions (157 patients), and pneumothorax (108
patients). The pleural effusions were mainly malig-
nant effusions, and the pneumothorax was sponta-
neous, both primary (where the underlying lung is
healthy) and secondary (where the pneumothorax
occurs as a complication of some underlying
pulmonary disease).12,24 All the studies were single
center except the study by Olivares-Torres et al.,23
which was multi-centric. Tube thoracostomy was
used in 144 patients and thoracoscopy in 121
patients.
There were no deaths related to chemical
pleurodesis with iodopovidone. The reported com-
plications of iodopovidone pleurodesis include
chest pain and systemic hypotension (three pa-
tients in the study by Olivares-Torres et al.23). The
occurrence of chest pain has been described to a
varying degree by different authors with one study
describing it as a universal occurrence.12 However,
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Table 1 Details of the studies using iodopovidone for chemical pleurodesis.
Study Patient
(n)
Diagnosis Method of
pleurodesis
Success rate n [%];
(95% CI)
(1) Echavarria et al.17
(1991); prospective,
single-center
15 Malignant pleural
effusion
Tube Thoracostomy;
Iodopovidone with
normal saline
15 [100]; (81.9–100)
(2) Morales-Gomez
et al.21 (1993);
prospective, single-
center
39 Malignant pleural
effusion
Tube Thoracostomy;
Iodopovidone with
normal saline
33 [84.6]; (69.5–94.1)
(3) Kelly Garcia et al.22
(1997); prospective,
single-center
14 Malignant pleural
effusion
Tube Thoracostomy;
Iodopovidone with
normal saline
9 [64.3]; (35.1–87.2)
(4) Olivares-Torres
et al.23 (2002);
prospective, multi-
center
52 Pleural effusion (44
malignant, 8 non
malignant)
Tube Thoracostomy
(12); Thoracoscopy
(40); Iodopovidone
with normal saline
50 [96.2]; (86.8–99.5)
(5) Estrada Salo et al.24
(2003); retrospective,
single-center
81 Spontaneous
pneumothorax
Thoracoscopy;
Iodopovidone
hydroalcoholic
solution
76 [93.8]; (86.2–97.9)
(6) Agarwal et al.12
(2006); prospective,
single-center
64 Pleural effusion (36
malignant, 1 non-
malignant)
Spontaneous
pneumothorax (27)
Tube Thoracostomy;
Iodopovidone with
normal saline
57 [89.1]; (78.8–95.5)
Non-English, CI confidence intervals.
Figure 1 Forest plot showing the success rate of
iodopovidone pleurodesis with 95% confidence intervals.
Efficacy and safety of iodopovidone in chemical pleurodesis 2045
none of the studies have measured pain system-
atically except the study by Agarwal et al.12 where
the authors have used Visual Analog Scale for
measurement of pain.
The success rate was not significantly different
whether tube thoracostomy (126/144; 87.5%, 95%
CI 80.9–92.4) or thoracoscopy (114/121; 94.2%, 95%
CI 88.4–97.6) was used for pleurodesis [P ¼ 0.06] or
whether the etiology was pleural effusion (139/
157; 88.5%, 95% CI 82.5–93.1) or pneumothorax
(101/108; 93.5%, 95% CI 87.1–97.4) [P ¼ 0:17].
Discussion
Chemical pleurodesis is a well-accepted therapy for
patients with recurrent pleural effusions and
pneumothorax, either with tube thoracostomy or
thoracoscopy. The question is the choice of the
sclerosing agent, which is not only determined by
the efficacy of the agent but also by its cost,
accessibility, safety, ease of administration and the
number of administrations to achieve a complete
response. In a review of English literature from
1966 to 1994, which included 1168 patients, talc
was the most effective chemical agent for malig-
nant pleural effusions, with a complete success
rate of 93% compared with Corynebacterium
parvum (76%), tetracycline (67%), doxycycline
(72%) and bleomycin (54%).3 Furthermore, in 32
case series of 723 patients of predominantly
malignant effusions, talc was effective either
completely or partially in 659 (91%) of cases.2 In a
meta-analysis,26 talc was found to be the most
effective agent for pleurodesis, and thoracoscopic
pleurodesis the preferred technique for pleurodesis
based on efficacy. There was no evidence for an
increase in mortality following talc pleurodesis.
Still, there are serious concerns about the safety of
talc. Talc is known to cause systemic embolization,
and is a potential cause of ARDS and respiratory
failure.15,16 Moreover, pharmaceutical talc (Steri-
talc) with well-described limits25 is not readily
available in many countries including India, and
there have been attempts in even using non-
pharmaceutical talc for pleurodesis.27
Iodopovidone is a topical antiseptic and has been
shown to be safe and effective in several stu-
dies.12,23 The precise mode of action of iodopovi-
done remains unclear, but it leads to enhanced
pleural fibrosis which may be related to the low pH
(pH, 2.97) of the sclerosing solution,23 or to the
strong oxidative and cytotoxic properties of iodine
that can induce a potent inflammatory response.28
Also iodopovidone has anti-exudative properties
which may be related to the chelation of pro-
teins.29 Theoretically the mechanism could also be
similar to that described recently for talc i.e.
production of fibroblast growth factor.30
Meta-analysis is a statistical procedure that
integrates the results of several relevant indepen-
dent studies, and allows one to arrive at a common
conclusion from an entire body of research. It
provides a more precise estimate of a treatment
effect, and may explain heterogeneity between the
results of individual studies.31 Although generally
applied to randomized controlled trials, a growing
number of meta-analyses of observational studies
in epidemiology (MOOSE) have appeared in the
literature.32,33
We therefore used the MOOSE methodology,32
and pooled the data on the efficacy and safety of
chemical pleurodesis with iodopovidone. In our
study, we assessed heterogeneity by visual inspec-
tion of the Forest plots in absence of any valid
described technique to describe heterogeneity in
abstract patient data observational study meta-
analyses. Visual inspection of Forest plots to assess
study heterogeneity is useful even when formal
statistical tests fail to detect significant hetero-
geneity, as these statistical tests are underpowered
to detect clinically important heterogeneity, espe-
cially when the number of outcomes, number of
patients, or number of trials is modest. Moreover, it
is important to avoid concluding that no hetero-
geneity exists among studies by relying solely on
statistical tests.20
The summary success rate of iodopovidone
pleurodesis in our study was 90.6%, which is almost
equal to the efficacy of talc pleurodesis (93%)2 and
other inexpensive agents used for chemical pleur-
odesis which include silver nitrate (75–90%) and
quinacrine (64–100%).34 The efficacy of iodopovi-
done was regardless of the etiology (pleural
effusion vs. pneumothorax) or the technique (tube
thoracostomy vs. thoracoscopy) used for perform-
ing pleurodesis. Importantly, talc causes lung injury
with more than 35 cases of ARDS related to talc
reported in the literature;15 iodopovidone, on the
other hand is associated with minimal side effects
although the experience with iodopovidone vis-a`-
vis talc is minimal.
The only significant side effect of iodopovidone is
the occurrence of chest pain, which has been
described to a different degree in various studies.
The most likely reason for this is because of
different procedures used for performing the
pleurodesis (tube thoracostomy vs. thoracoscopy).
The studies that have employed thoracoscopy have
patients who are already receiving anesthesia
where pain measurement is likely to be fallacious.
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Moreover, except in one study,12 none have system-
atically assessed the occurrence of chest pain.
Hypotension was reported by only one study
that too in only three patients.23 It is not clear
whether the hypotension was an anaphylactoid
reaction or pain-associated vasovagal reaction.
However, iodine can cause severe allergic reac-
tions, especially in patients with allergic diathesis,
and thus one should be prepared to deal with this
emergency. Finally, iodine may also precipitate
thyrotoxicosis in patients with subclinical hyper-
thyroidism (Jod-Basedow effect).
In conclusion, iodopovidone is an effective, safe,
readily available, and inexpensive alternative to
achieve chemical pleurodesis in cases of recurrent,
pleural effusions and pneumothoraces regardless of
their etiology.
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